Post List

All posts; Tags Include "Clinical Research"

(Modify Search »)

  • November 4, 2010
  • 10:45 AM
  • 1,180 views

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

by Sally Church in Pharma Strategy Blog

This morning I was delighted to see that one of my favourite medical doctors on Twitter, Dr Anas Younes from MD Anderson, has published a paper in the New England Journal of Medicine on a clinical trial of a promising … Continue reading →... Read more »

Younes, A., Bartlett, N., Leonard, J., Kennedy, D., Lynch, C., Sievers, E., & Forero-Torres, A. (2010) Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. New England Journal of Medicine, 363(19), 1812-1821. DOI: 10.1056/NEJMoa1002965  

  • November 3, 2010
  • 12:11 PM
  • 1,144 views

Metastatic melanoma – what’s new on the horizon?

by Sally Church in Pharma Strategy Blog

Metastatic melanoma is quite a hot topic right now with a rich pipeline of products in development after a decade of little or no progress.  Of course, it is a bit like three London buses coming along at once after … Continue reading →... Read more »

  • November 3, 2010
  • 08:08 AM
  • 1,338 views

How To Form A Habit

by Lorimer Moseley in BodyInMind

We’ve all wondered how to get our patients to change their life habits (to the better of course…in our minds). In fact, the behavioural and physical therapies depend on us being able to convince patients to develop new habits – to  bend and straighten their knees a few times before getting up from prolonged sitting [...]... Read more »

Lally, P., van Jaarsveld, C., Potts, H., & Wardle, J. (2009) How are habits formed: Modelling habit formation in the real world. European Journal of Social Psychology. DOI: 10.1002/ejsp.674  

  • November 2, 2010
  • 08:13 AM
  • 1,016 views

Dendritic Polyglycerol Sulfates for Inflammatory Diseases

by Michael Long in Phased

Rainer Haag (Freie Universitat Berlin) and coworkers have synthesized a branched polymer that potently inhibits L and P selectin activity in mice, and thus shows promise as a treatment for inflammatory diseases.... Read more »

Dernedde, J., Rausch, A., Weinhart, M., Enders, S., Tauber, R., Licha, K., Schirner, M., Zugel, U., von Bonin, A., & Haag, R. (2010) Dendritic polyglycerol sulfates as multivalent inhibitors of inflammation. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.1003103107  

  • November 1, 2010
  • 01:42 PM
  • 1,167 views

Crizotinib in ALK-rearranged cancer mutations

by Sally Church in Pharma Strategy Blog






While reading the latest New England Journal of Medicine, it was hard not to notice the focus on ALK mutations and crizotinib (Pfizer), with four articles in all on the topic, including a full original article, two brief reports and [...]... Read more »

Morris, S., Kirstein, M., Valentine, M., Dittmer, K., Shapiro, D., Saltman, D., & Look, A. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science, 263(5151), 1281-1284. DOI: 10.1126/science.8122112  

Soda, M., Choi, Y., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H.... (2007) Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561-566. DOI: 10.1038/nature05945  

Kwak, E., Bang, Y., Camidge, D., Shaw, A., Solomon, B., Maki, R., Ou, S., Dezube, B., Jänne, P., Costa, D.... (2010) Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer. New England Journal of Medicine, 363(18), 1693-1703. DOI: 10.1056/NEJMoa1006448  

Hallberg, B., & Palmer, R. (2010) Crizotinib — Latest Champion in the Cancer Wars?. New England Journal of Medicine, 363(18), 1760-1762. DOI: 10.1056/NEJMe1010404  

Butrynski, J., D'Adamo, D., Hornick, J., Dal Cin, P., Antonescu, C., Jhanwar, S., Ladanyi, M., Capelletti, M., Rodig, S., Ramaiya, N.... (2010) Crizotinib in -Rearranged Inflammatory Myofibroblastic Tumor . New England Journal of Medicine, 363(18), 1727-1733. DOI: 10.1056/NEJMoa1007056  

  • October 29, 2010
  • 09:00 AM
  • 905 views

What's in a placebo? Mike Adams certainly doesn't know. [Respectful Insolence]

by Orac none@example.com in Food Matters

If there's one thing that confounds advocates of so-called "complementary and alternative medicine" (CAM), it's the placebo effect. That's because, whenever most such remedies are studied using rigorous clinical trial design using properly constituted placebo controls, they almost always end up showing effects no greater than placebo effects. That's the main reason why they frequently suggest that, you know, all those rigorous, carefully constructed randomized placebo-controlled clinical trials ........ Read more »

Golomb BA, Erickson LC, Koperski S, Sack D, Enkin M, & Howick J. (2010) What's in placebos: who knows? Analysis of randomized, controlled trials. Annals of internal medicine, 153(8), 532-5. PMID: 20956710  

  • October 29, 2010
  • 08:44 AM
  • 2,196 views

Weight-loss variability in response to the same diet

by Peter Janiszewski, Ph.D. in Obesity Panacea

Whoever said weight loss was a straightforward process has probably never tried to go from a BMI of 40 down to 24 kg/m2. I must admit that only a few years back, in the early stages of my graduate training, I was equally naive. I thought: it’s a case of simple math – once your energy expenditure exceeds your energy intake, you lose weight.
It certainly sounds simple, and yet it rarely is that simple in practice.
Take for example a recent study published in the November issue of Obesi........ Read more »

  • October 29, 2010
  • 08:31 AM
  • 2,072 views

What's in a placebo? Mike Adams certainly doesn't know.

by Orac in Respectful Insolence

If there's one thing that confounds advocates of so-called "complementary and alternative medicine" (CAM), it's the placebo effect. That's because, whenever most such remedies are studied using rigorous clinical trial design using properly constituted placebo controls, they almost always end up showing effects no greater than placebo effects. That's the main reason why they frequently suggest that, you know, all those rigorous, carefully constructed randomized placebo-controlled clinical trials ........ Read more »

Golomb BA, Erickson LC, Koperski S, Sack D, Enkin M, & Howick J. (2010) What's in placebos: who knows? Analysis of randomized, controlled trials. Annals of internal medicine, 153(8), 532-5. PMID: 20956710  

  • July 9, 2010
  • 01:37 AM
  • 906 views

Friday Weird Science: The Human Penis Bone

by Evil Monkey in Neurotopia

Today's post is some seriously OLD science. Old science and WEIRD science, coming to you courtesy of Mt. Sinai hospital in NYC, 1913.

And it's also the WEIRDEST conjunction of this:



And this:



That Sci has ever seen.

Gerster AG, Mandlebaum FS. "XI. On the Formation of Bone in the Human Penis." Annals of Surgery, 1913.

The pictures below are curiously safe for work. I suppose that picture up there wasn't. oops. Read the rest of this post... | Read the comments on this post...... Read more »

GERSTER, A., & MANDLEBAUM, F. (1913) ON THE FORMATION OF BONE IN THE HUMAN PENIS. Annals of Surgery, 57(6), 896-901. DOI: 10.1097/00000658-191306000-00012  

  • November 2, 2009
  • 08:37 PM
  • 2,180 views

Hot News: Curry, Curcumin, Cancer & Cure

by Laika in Laika's Medliblog

*Hot* News via Twitter and various news media a few days ago. Big headlines tell the following in respectively The Sun, Herald, Ireland, BBC News / NHS Health and Reuters:
Curry is a ‘cure for cancer‘
Spices in curry may help cure cancer
Curry spice ‘kills cancer cells‘
Scientists say curry compound kills cancer cells
The message of these headlines [...]... Read more »

  • November 30, 1999
  • 12:00 AM
  • 2,250 views

Dr. A H Bandivdekar finds the inhibitor for sexual transmission of HIV virus.

by B V Waghmare in HIV virus and antiretroviral drugs and antiAIDS vaccine research and developmets

Dr. A H Bandivdekar Indian scientist found the exact way by which HIV virus gains entry in to human blood in sexual transmission of HIV virus, which is one of the biggest reason for HIV virus infections and AIDS.
There are certain individuals who are tested positive and do not develop symptoms of AIDS or AIDS this is because there is diffrerance in their genetic constitution.
In latancy period there is a resistance for replication of HIV virus in lymphocytes in these infected individuals. The........ Read more »

B V Waghmare. (2011) Dr. A H Bandivdekar finds the inhibitor for sexual transmission of HIV virus. . http://bvwaghmare.blogspot.com/. info:/bvwaghmare

  • November 30, 1999
  • 12:00 AM
  • 2,421 views

genetically engineered stem cell treatment, gen therapy for HIV virus infection, AIDS.

by B V Waghmare in HIV virus and antiretroviral drugs and antiAIDS vaccine research and developmets

Scientists have collected stem cells from patients own body , and engineered them , and induced in to them gens which expresses three RNA-based anti-HIV moieties as follows .
1.tat/rev short hairpin RNA,
2.TAR decoy,
3.CCR5 ribozyme.
Amongst these anti HIV moieties CCR5 ribozyme is capable of hampering production of CCR5 protein a essential protein which is responsible for HIV virus entry in to new host cell , there it can lower a viral load , in to patient and help anti retroviral drugs t........ Read more »

B V Waghmare. (2010) Information on genetically engineered stem cell treatment, gen therapy for HIV virus infection, AIDS. . bvwaghmare.blogspot.com. info:/

  • November 30, 1999
  • 12:00 AM
  • 2,138 views

Novel Approach for anti AIDS drug development.

by B V Waghmare in HIV virus and antiretroviral drugs and antiAIDS vaccine research and developmets

HIV virus when it incorporates its DNA in human T-Lymphocytes , it integrates in a very controlled manner so that it takes care that our T-Lymphocytes cells do not get destroyed before they code and generate HIV virus proteins and genetic material and form enough new HIV viruses.
Professors Abraham Loyter, Assaf Friedler and their colleagues have reported that they have developed a peptide called as “MIX”

Peptide “MIX” is able to increase activity of HIV virus enzyme ........ Read more »

B V Waghmare. (2010) Developing a peptide that kills HIV virus. bvwaghmare.blogspot.com. info:/

  • November 30, 1999
  • 12:00 AM
  • 1,935 views

HIV vaccine research: Protein which train B cells for production of antibodies against HIV which successfully neutralize HIV

by B V Waghmare in HIV virus and antiretroviral drugs and antiAIDS vaccine research and developmets

HIV virus rapidly undergoes mutation, which is main hurdle in developing vaccine against HIV.There is a region on HIV virus which shows less variations, called as Cd4 binding site ,therefore a protein which stimulate antibody formation against this region can be developed and used as a vaccine.
Researchers at Vaccine Research Center (VRC) and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health have studied genes which code for such proteins which can........ Read more »

B V Waghmare. (2011) HIV vaccine development : Proteins which trains B Cells for production of antibodies which successfully neutralize HIV by binding with it . http://bvwaghmare.blogspot.com. info:/(DOI/arXiv/etc.)

  • November 30, 1999
  • 12:00 AM
  • 1,822 views

Using folate receptor alpha flurorescence imaging in ovarian cancer

by Sally Church in Pharma Strategy Blog

The idea behind this concept is that fluorescence technology can be used to help guide ovarian cancer surgery more effectively, since the tumors tend to be small and hard to see for surgeons performing the excision.... Read more »

van Dam, G., Themelis, G., Crane, L., Harlaar, N., Pleijhuis, R., Kelder, W., Sarantopoulos, A., de Jong, J., Arts, H., van der Zee, A.... (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nature Medicine. DOI: 10.1038/nm.2472  

  • November 30, 1999
  • 12:00 AM
  • 1,187 views

Interlukin 32 biomarker which predict relapse of mycobacterium tuberculosis

by B V Waghmare in HIV virus and antiretroviral drugs and antiAIDS vaccine research and developmets

Interlukin 32 a protien which is found in people which do test positie for mycobacterium tuberculosis infection but do not develop pulmonary disease, it is found that interlukin is important in killing micobacterium, thereby protect them from TB disease, this interleukin 32 can be used therapeutically in patients suffering with TB along with chemotherapy, which will enhance efficacy of anti tuberculosis chemo therapy... Read more »

B V Waghmare. (2014) Interlukin 32 biomarker that will predict relapse of tuberculosis infection and will be used in treatment of TB. http://www.medicalwebsite.org/2014/09/protein-that-protect-from-tb-infection.html. info:/

  • November 30, 1999
  • 12:00 AM
  • 699 views

The Fatal Flaw in Trial of Continuous or Interrupted Chest Compressions during CPR

by Rogue Medic in Rogue Medic

This is not a study that has a valid control group to determine if there is any benefit from ventilation. There is no group that does not receive ventilations, so it is like a study of one type of blood-letting vs. another type of blood-letting with the researchers taking for granted that blood-letting does improve outcomes. That is not a problem if blood-letting actually improves outcomes.

Should we take it for granted that blood-letting improves outcomes and that the only hypothesis worth s........ Read more »

Nichol, G., Leroux, B., Wang, H., Callaway, C., Sopko, G., Weisfeldt, M., Stiell, I., Morrison, L., Aufderheide, T., Cheskes, S.... (2015) Trial of Continuous or Interrupted Chest Compressions during CPR. New England Journal of Medicine, 2147483647. DOI: 10.1056/NEJMoa1509139  

Alldredge BK,, Gelb AM,, Isaacs SM,, Corry MD,, Allen F,, Ulrich S,, Gottwald MD,, O’Neil N,, Neuhaus JM,, Segal MR,.... (2001) A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus. New England Journal of Medicine, 345(25), 1860-1860. DOI: 10.1056/NEJM200112203452521  

  • November 30, 1999
  • 12:00 AM
  • 1,385 views

The Fatal Flaw in Trial of Continuous or Interrupted Chest Compressions during CPR

by Rogue Medic in Rogue Medic

This is not a study that has a valid control group to determine if there is any benefit from ventilation. There is no group that does not receive ventilations, so it is like a study of one type of blood-letting vs. another type of blood-letting with the researchers taking for granted that blood-letting does improve outcomes. That is not a problem if blood-letting actually improves outcomes.

Should we take it for granted that blood-letting improves outcomes and that the only hypothesis worth s........ Read more »

Nichol, G., Leroux, B., Wang, H., Callaway, C., Sopko, G., Weisfeldt, M., Stiell, I., Morrison, L., Aufderheide, T., Cheskes, S.... (2015) Trial of Continuous or Interrupted Chest Compressions during CPR. New England Journal of Medicine, 2147483647. DOI: 10.1056/NEJMoa1509139  

Alldredge BK,, Gelb AM,, Isaacs SM,, Corry MD,, Allen F,, Ulrich S,, Gottwald MD,, O’Neil N,, Neuhaus JM,, Segal MR,.... (2001) A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus. New England Journal of Medicine, 345(25), 1860-1860. DOI: 10.1056/NEJM200112203452521  

  • November 30, 1999
  • 12:00 AM
  • 1,208 views

The PROCAMIO Trial – IV Procainamide vs IV Amiodarone for the Acute Treatment of Stable Wide Complex Tachycardia

by Rogue Medic in Rogue Medic

This is a very interesting trial that may surprise the many outspoken amiodarone advocates, but it should not surprise anyone who pays attention to research.

ALPS showed that we should stop giving amiodarone for unwitnessed shockable cardiac arrest. The lead researcher is still trying to spin amiodarone for witnessed shockable cardiac arrest, even though the results do not show improvement in the one outcome that matters – leaving the hospital with a brain that still works.[1],[2],[3]... Read more »

Kudenchuk PJ, Brown SP, Daya M, Rea T, Nichol G, Morrison LJ, Leroux B, Vaillancourt C, Wittwer L, Callaway CW.... (2016) Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. The New England journal of medicine, 374(18), 1711-22. PMID: 27043165  

Marill KA, deSouza IS, Nishijima DK, Senecal EL, Setnik GS, Stair TO, Ruskin JN, & Ellinor PT. (2010) Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: an historical multicenter comparison. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, 17(3), 297-306. PMID: 20370763  

Marill KA, deSouza IS, Nishijima DK, Stair TO, Setnik GS, & Ruskin JN. (2006) Amiodarone is poorly effective for the acute termination of ventricular tachycardia. Annals of emergency medicine, 47(3), 217-24. PMID: 16492484  

Kułakowski P, Karczmarewicz S, Karpiński G, Soszyńska M, & Ceremuzyński L. (2000) Effects of intravenous amiodarone on ventricular refractoriness, intraventricular conduction, and ventricular tachycardia induction. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2(3), 207-15. PMID: 11227590  

Bonny A, De Sisti A, Márquez MF, Megbemado R, Hidden-Lucet F, & Fontaine G. (2012) Low doses of intravenous epinephrine for refractory sustained monomorphic ventricular tachycardia. World journal of cardiology, 4(10), 296-301. PMID: 23110246  

Kowey PR. (1988) The calamity of cardioversion of conscious patients. The American journal of cardiology, 61(13), 1106-7. PMID: 3364364  

  • November 30, 1999
  • 12:00 AM
  • 5 views

DHM attenuates obesity-induced slow-twitch-fiber decrease via FLCN/FNIP1/AMPK pathway

by Joana Guedes in BHD Research Blog

Obesity is often associated with decreases in the proportion of skeletal muscle slow-twitch fibers and insulin sensitivity. Slow-twitch fibers are rich in mitochondria and utilize fatty acid oxidative phosphorylation for energy production. In their new study, Zhou et al. (2017) explore the role of the FLCN/FNIP1/AMPK signalling pathway in obesity-induced reductions in slow-twitch fibers and insulin sensitivity in skeletal muscle using high-fat-diet-induced (HFD) obese mice, ob/ob mutant mice, an........ Read more »

join us!

Do you write about peer-reviewed research in your blog? Use ResearchBlogging.org to make it easy for your readers — and others from around the world — to find your serious posts about academic research.

If you don't have a blog, you can still use our site to learn about fascinating developments in cutting-edge research from around the world.

Register Now

Research Blogging is powered by SMG Technology.

To learn more, visit seedmediagroup.com.